Mkts

Tarsus Pharmaceuticals, Inc.

NASDAQ: TARS
$73.01-4.66 (-6.00%)
As of Nov 20, 4:00 PM ET

Key statistics

Day range
72.5778.11
52-week range
53.8991.53
Today
Open77.09
Previous close73.01
Volume—
Valuation
Market cap3.60B
P/E ratio—
EPS (TTM)-15.18
Income & risk
Dividend / yield—
Beta0.38
Avg volume860.3K
Discussion

TARS News

Stories mentioning TARS from around the web — every one is an open thread, so give it a like or add your take.

All news →

Loading news…

Financial statements

Financial statements

As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.

Line itemQ1 '26Mar 31Q4 '25Dec 31Q3 '25Sep 30Q2 '25Jun 30Q1 '25Mar 31Q4 '24Dec 31Q3 '24Sep 30Q2 '24Jun 30
Income Statement
Revenue162,054151,668118,697102,66078,33566,40848,11840,813
Cost of Goods Sold9,3965,211
Gross Profit152,65873,124
Operating Expenses
Research & Development22,35118,03516,28415,59414,40916,87312,12812,319
Sales General & Admin136,429130,682108,633103,01384,99569,03057,91058,792
Total Operating Expenses
Operating Income (Loss)(6,122)(7,976)(14,529)(22,184)(26,280)(24,421)(25,162)(33,302)
Interest Income
Interest Expense
Other Expense(87.00)(74.00)98.00(145.00)(81.00)(27.00)67.00(65.00)
Pretax Income
Tax Provision2,3520.00
Net Income (Loss)(6,967)(8,373)(12,585)(20,340)(25,120)(23,113)(23,420)(33,290)
Earnings Per Share (Basic)(0.16)(0.20)(0.30)(0.48)(0.64)(0.61)(0.61)(0.88)
Earnings Per Share (Diluted)(0.16)(0.20)(0.30)(0.48)(0.64)(0.61)(0.61)(0.88)
Weighted Average Shares Outstanding (Basic)42,95741,78442,60842,36039,34537,60538,38237,823
Weighted Average Shares Outstanding (Diluted)42,95741,78442,60842,36039,34537,60538,38237,823

Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.

Key facts

About TARS

Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) is a stock listed on the Nasdaq Stock Market under the ticker symbol TARS. It last traded at $73.01 (Nov 20, 2026, 4:00 PM ET), down 6.0% on the day. That gives Tarsus Pharmaceuticals a market capitalisation of $3.6B.

Over the past 52 weeks TARS has traded between $53.89 and $91.53.

Revenue for the quarter ended Mar 31, 2026 was $162.1M; a net loss of $7.0M. Revenue was up 107% from $78.3M in the quarter ended Mar 31, 2025.

Last 4 quarters
Quarter endedRevenueNet incomeMargin
Mar 31, 2026$162.1M-$7.0M-4.3%
Dec 31, 2025$151.7M-$8.4M-5.5%
Sep 30, 2025$118.7M-$12.6M-10.6%
Jun 30, 2025$102.7M-$20.3M-19.8%

From Tarsus Pharmaceuticals’s quarterly (10-Q) filings, in US dollars.

Latest News

Market news from around the web — every story is an open thread, so give it a like or add your take.

All news →

Loading news…